Scienture Holdings, Inc. (SCNX)
NCM · Healthcare · Pharmaceutical Retailers
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 590K | -169K | 56K |
| Gross Profit | 0.00 | 575K | -244K | 54K |
| Operating Income | -5.2M | -4.4M | -3.2M | -3.5M |
| Net Income | -6.7M | -3.6M | -28.1M | -3.4M |
| Diluted EPS | $-0.48 | $-0.19 | $nan | $-0.08 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 10.3M | 1.4M | 137K | 432K |
| Gross Profit | 5.5M | 49K | 6K | 331K |
| Operating Income | -2.0M | -4.4M | -14.7M | -16.2M |
| Net Income | -3.5M | -17.8M | 9.1M | -41.5M |
| Diluted EPS | $-6.15 | $-23.35 | $2.48 | $-2.70 |